<DOC>
	<DOCNO>NCT02510599</DOCNO>
	<brief_summary>The purpose study evaluate effect solithromycin hepatic histology biomarkers patient nonalcoholic steatohepatitis .</brief_summary>
	<brief_title>Safety Efficacy Solithromycin Treatment Nonalcoholic Steatohepatitis Without Cirrhosis</brief_title>
	<detailed_description>Patients administer solithromycin 13 week regular safety visit liver biopsy baseline treatment .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Histologic evidence NASH base liver biopsy obtain within 180 day NAS &gt; = 5 Able swallow capsule intact Symptoms acute liver disease Cirrhosis liver biopsy Positive HIV Hepatitis test Primary Biliary Cirrhosis Poorly control diabetes HgA1C &gt; 8.5 % ALT &gt; 4fold upper limit normal QTcF &gt; 450 msec CrCl &lt; 40 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NASH</keyword>
	<keyword>Liver disease</keyword>
</DOC>